/ WHO WE ARE

RiverVest is a leading venture capital firm building life science companies to address significant unmet medical needs.

8

FUNDS

Since 2000

/ EXPERT INSIGHT

Global Clinical Trial Investigates Novel Heart Failure Treatment

VCs take significant but careful risks in funding novel efforts to address unmet medical needs, as RiverVest portfolio company Alleviant Medical aims to do for large underserved subsets of heart failure patients. Read RiverVest’s latest Expert Insight to learn why we chose to invest in Alleviant and its novel, no-implant shunt therapy. 

/ NEWS

ST. LOUIS, December 14, 2023 – RiverVest Venture Partners today announced the promotions of three current team members:  Karen Spilizewski and Izaac Zike, Ph.D. to Managing Director and Pascal Krotee, Ph.D. to Principal.

/ CASE STUDY

Good Therapeutics, founded in 2016 by John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. Even better, Mulligan and company retained its platform and the ability to mine it for innovative drugs to fight cancer and other diseases. 

28

COMMERCIAL PRODUCTS

Currently Treating Patients
rivervest map dots graphic image

RiverVest’s Footprint Increases Its Opportunity Set

St. Louis

101 S. Hanley Road, Suite 1850
St. Louis, MO 63105
Phone: (314) 726.6700

San Diego

10996 Torreyana Road, Suite 280
San Diego, CA 92121
Phone: (314) 726.6700

Cleveland

11000 Cedar Avenue
Cleveland, OH 44106
Phone: (216) 658.3982
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation. Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.
© Copyright 2024 RiverVest® All Rights Reserved. | Privacy Policy

Subscribe to our newsletter

Rivervest Contact